| 研究課題/領域番号 |
18K07229
|
|---|
| 研究機関 | 京都大学 |
|---|
研究代表者 |
|
|---|
| 研究期間 (年度) |
2018-04-01 – 2021-03-31
|
| キーワード | P53 mRNA / mRNA translation / IRES / Cancer mutation / P53 isoform / Delta160p53 |
|---|
| 研究実績の概要 |
We had already completed tasks 1 and 2. We have now completed the colony formation assays as well as the xenograft studies. We had to stop experiments for almost 2 months due to the COVID19 pandemic but are still on time. Our last challenge will be to try to screen for a drug that can inhibit the IRES and inactivate D160p53.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
Task 1 was concluded last year
Task 2 was concluded last year
Task 3 has now been concluded (colony formation assays and tumorigenesis assay in the xenograft model showing that IRESd160 and D160p53 are tumorigenic)
Task 4 is under way. This is the last one (drug screening to identify a small compound that might inhibit d160 expression)
|
| 今後の研究の推進方策 |
Everything is going on time, even if we had to stop research for 2 months due to COVID19 (and we are still now mostly stopped), I still think we should be able to conclude the project on time. Our future plan is to try to identify a small drug that inhibits D160p53 expression and might be used for cancer therapy
|
| 次年度使用額が生じた理由 |
We used a less money than expected, but we'll probably need it this year to finalize the project.
|
